Penumbra, Inc. (NYSE:PEN) Holdings Lowered by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB lowered its stake in Penumbra, Inc. (NYSE:PEN) by 16.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,000 shares of the company’s stock after selling 6,000 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Penumbra were worth $7,124,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of PEN. Pallas Capital Advisors LLC boosted its stake in shares of Penumbra by 3.8% during the 4th quarter. Pallas Capital Advisors LLC now owns 1,108 shares of the company’s stock worth $263,000 after acquiring an additional 41 shares in the last quarter. Advisors Asset Management Inc. boosted its holdings in shares of Penumbra by 11.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 416 shares of the company’s stock worth $81,000 after buying an additional 43 shares during the period. Pacer Advisors Inc. raised its holdings in Penumbra by 1.0% in the 4th quarter. Pacer Advisors Inc. now owns 5,721 shares of the company’s stock worth $1,359,000 after acquiring an additional 57 shares during the period. Legacy Wealth Asset Management LLC lifted its position in Penumbra by 3.9% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 1,731 shares of the company’s stock worth $336,000 after acquiring an additional 65 shares during the last quarter. Finally, UMB Bank n.a. grew its position in shares of Penumbra by 57.4% in the fourth quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after purchasing an additional 70 shares during the last quarter. 88.88% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Penumbra news, CEO Adam Elsesser sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $237.28, for a total value of $3,559,200.00. Following the transaction, the chief executive officer now directly owns 852,582 shares of the company’s stock, valued at approximately $202,300,656.96. This trade represents a 1.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Johanna Roberts sold 600 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $239.74, for a total transaction of $143,844.00. Following the sale, the executive vice president now owns 64,044 shares of the company’s stock, valued at $15,353,908.56. The trade was a 0.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,819 shares of company stock worth $8,129,483 in the last 90 days. Corporate insiders own 5.00% of the company’s stock.

Penumbra Trading Down 0.3 %

PEN stock opened at $260.68 on Friday. The business has a fifty day moving average price of $252.35 and a 200 day moving average price of $220.54. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.82 and a quick ratio of 3.25. Penumbra, Inc. has a fifty-two week low of $148.00 and a fifty-two week high of $277.89. The stock has a market capitalization of $10.00 billion, a price-to-earnings ratio of 303.12, a P/E/G ratio of 1.92 and a beta of 0.53.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PEN. Oppenheimer began coverage on Penumbra in a research report on Tuesday, December 17th. They issued an “outperform” rating and a $275.00 price objective for the company. BTIG Research raised their price target on shares of Penumbra from $232.00 to $270.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Canaccord Genuity Group boosted their price objective on shares of Penumbra from $260.00 to $323.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Needham & Company LLC reissued a “hold” rating on shares of Penumbra in a research report on Thursday, October 31st. Finally, Citigroup upped their price target on Penumbra from $220.00 to $245.00 and gave the company a “neutral” rating in a report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $261.36.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.